ImmunityBio, Inc.

ImmunityBio, Inc.

164.00
MXN
0.00
(0.00%)
-19.42EPS
Mar 02Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.01
- -
- -
- -
- -
0.02
0.12
0.18
Basic EPS, GAAP
-0.41
-0.58
-0.89
-1.04
-1.15
-0.59
-0.38
-1.08
Free Cash Flow per Basic Share
-0.41
-0.45
-0.79
-1.09
-0.78
-0.57
-0.34
-0.29
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.31
-0.61
-1.06
-0.87
-0.57
-0.49
-1.08
Tangible Book Value per Share
- -
-0.32
-0.61
-1.11
-0.9
-0.59
-0.51
-1.09
Basic Weighted Avg Shares
383
383
389
400
509
697
920
1,032
Sales/Revenue/Turnover
2
1
1
- -
1
15
113
183
Operating Margin (%)
-7,095.87
-34,747.11
-35,361.88
-146,090.42
-58,097.11
-2,334.23
-226
-150.16
Depreciation Expense
14
13
14
18
19
18
16
17
Net Income, GAAP
-158
-222
-347
-417
-583
-414
-351
-1,110
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-7,165.17
-36,669.59
-37,129.55
-173,569.58
-93,761.41
-2,804.77
-310.18
-607.79
Working Capital
- -
44
-35
-360
236
130
253
321
LT Debt
- -
271
343
289
721
497
511
862
Total Equity
- -
-118
-244
-450
-586
-488
-500
-1,145
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
8
8
7
LT Borrowings
678
774
835
LT Finance Leases
33
31
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,047
1,053
1,064
Market Capitalization
- -
- -
- -

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
453
439
419
Cash, Cash Equivalents & STI
381
357
334
Accounts Receivable, Net
43
53
54
Inventories
1
2
- -
Total Current Liabilities
68
77
98
Payables & Accruals
47
69
91
ST Debt
8
8
7
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
41.24%
2.34%
Free Cash Flow
- -
17.66%
-22.34%
Net Income, GAAP
- -
14.46%
-15.03%
Sales/Revenue/Turnover
- -
615.63%
668.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
1
6
8
15
2025
17
26
32
38
113
2026
44
51
49
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.2
-0.12
-0.08
-0.59
2025
-0.15
-0.1
-0.07
-0.06
-0.38
2026
-0.62
-0.22
-0.17
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Richard Adcock
Full Time Employees
691
Sector
Health technology
Industry
Pharmaceuticals: major
Address
3530 John Hopkins Court San Diego CA United States 92121
IPO Date
Jul 28, 2015
Business
ImmunityBio, Inc. (NASDAQ: IBRX) develops next-generation immunotherapies that bolster the natural immune system to fight cancers and infectious diseases; its platforms include antibody-cytokine fusion proteins such as the FDA-approved Anktiva (N-803/nogapendekin alfa inbakicept-pmln), an IL-15 superagonist used in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ; vaccine vectors encompassing DNA, RNA, and adenovirus-based technologies for personalized cancer vaccines and HPV-related therapies; and cell therapies featuring NK-92-derived natural killer cells like PD-L1 t-haNK, alongside T-cell therapies and macrophage activators that target solid tumors (pancreatic, lung, colorectal), liquid tumors, HIV, and Lynch syndrome-associated cancers. The company, founded in 2014 and headquartered in San Diego, California, with additional operations in Culver City, California, and Morrisville, North Carolina, operates as a vertically integrated, commercial-stage biotechnology firm conducting internal cGMP manufacturing and a robust clinical pipeline across multiple phases and indications in collaboration with the National Cancer Institute, Serum Institute of India Private Limited, and BeiGene, Ltd. Recent developments include FDA approval of Anktiva in April 2024, an $80 million equity financing via registered direct offering with institutional investors in July 2025 to support operations and clinical trials, and a partnership with nCartes announced in November 2024 to automate clinical trial data processes.

Company News

  • ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript

  • New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care

  • ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

  • IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%

  • Why ImmunityBio Stock Dropped 15% After Earnings Despite 53% Sales Growth. Is IBRX Now a Buy?

  • ImmunityBio Reports Wider Quarterly Loss

  • ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates

  • ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million

  • ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

  • ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial

  • ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

  • ImmunityBio, Inc. $IBRX Stake Trimmed by Davidson Kahn Capital Management LLC

  • ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer

  • ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment

  • ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors

  • FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer

  • ImmunityBio Stock Climbs Thursday: What's Going On?

  • FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

  • ImmunityBio (NASDAQ:IBRX) vs. Monte Rosa Therapeutics (NASDAQ:GLUE) Financial Survey

  • ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium